Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jaguar Health, Inc.

NASDAQ: JAGX · Life Sciences · 12 alerts · CIK 1585608

Share price
$0.3864Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jaguar Health, Inc. filings on SEC EDGAR ↗

9:15 AM ET 8-K
Financial Results

Jaguar Health Financial Results

Jaguar Health reported its third quarter 2026 financial results, highlighting a significant $10.1 million reduction in outstanding debt. The company is transitioning to a distribution and R&D model following its U.S. commercial licensing agreement with Woodward Specialty, focusing on its rare disease intestinal failure program for crofelemer.

6:40 AM ET 10-Q
Financial Results

Jaguar Health Q3 2026 Results: Net Loss of $5.83M, Loss Narrows

Jaguar Health reported a significant increase in total revenue to $23.8 million for the nine months ended September 30, 2026, primarily driven by $20.9 million in license revenue. Despite this, the company recorded a net loss of $9.9 million for the period, though this was a substantial improvement from the $30.8 million net loss in the prior year period.

Key figure
Net loss $5.83M
4:31 PM ET 8-K
Shareholder Meeting

Jaguar Health Shareholder Meeting

Jaguar Health held a special meeting of stockholders on November 6, 2026, where all six submitted proposals were approved. Key approvals included the issuance of common stock upon exchange of Series Q Preferred Stock and debt, the repricing of investor warrants to $1.00 per share, an increase in authorized shares for the 2014 Stock Incentive Plan, and the authorization for a potential reverse stock split at a ratio between 1-for-2 and 1-for-150.

2:16 PM ET 8-K
Other 8-K Filing

Jaguar Health Other 8-K Filing

Jaguar Health announced the automatic conversion of its Series R Convertible Preferred Stock into common stock on November 2, 2026. Each share of Series R Preferred Stock, which was previously issued as a special dividend, converted into five shares of common stock, resulting in a total of 13,345,986 shares of common stock outstanding.

5:08 PM ET 8-K
Stock Plan Amendment

Jaguar Health Stock Plan Amendment

Jaguar Health filed a proxy supplement regarding Proposal 3 for its upcoming special meeting, seeking shareholder approval to increase the 2014 Stock Incentive Plan's authorized shares to 378,859. This share reserve represents 14% of the company's issued and outstanding common stock on a fully diluted basis as of September 30, 2026. The supplement clarifies the share count following a special one-time dividend of Series R Preferred Stock and its subsequent conversion into common stock.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.